Yan ke xue bao = Eye science · 2007
[Blood vessel multiply and significance of expression of Cox-2, VEGF in pterygium].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yan Meirong, Li Zhengxian, Liu Gengxun, Peng Changfu, Zhou Yiming, Wang Fang
Аннотация
OBJECTIVE: To investigate the role of cyclooxygenases-2 (Cox-2) and vascular endothelial growth factor (VEGF) in the occurrence and development of human pterygium.
METHODS: The immunohistochemical elivision method was used to examine the expressions of Cox-2 and VEGF in 30 cases of pterygium and 15 cases with normal conjunctiva.
RESULTS: The positive rate of Cox-2 was 42.8% in resting stage, 84.6% in active stage, 90.0% in recurrent pterygium and 6.6% in normal conjunctiva. The positive rate of VEGF was 57.1% in resting stage, 69.2% in active stage, 100.0% in recurrent pterygium and 13.3% in the normal conjunctiva. There was significant difference in the expressions of Cox-2 and VEGF between the pterygium and normal conjunctiva (P < 0.05, P < 0.001).
CONCLUSIONS: There are high Cox-2 and VEGF expressions in pterygium, which suggests that there is abnormal blood vessel multiply in pterygium, and the Cox-2 and VEGF plays an important role in the incidence and development of pterygium. Specific Cox-2 and VEGF inhibitor become a new target for the therapy of pterygium. Specific Cox-2 and VEGF inhibitor become a new target for the therapy of pterygium.
METHODS: The immunohistochemical elivision method was used to examine the expressions of Cox-2 and VEGF in 30 cases of pterygium and 15 cases with normal conjunctiva.
RESULTS: The positive rate of Cox-2 was 42.8% in resting stage, 84.6% in active stage, 90.0% in recurrent pterygium and 6.6% in normal conjunctiva. The positive rate of VEGF was 57.1% in resting stage, 69.2% in active stage, 100.0% in recurrent pterygium and 13.3% in the normal conjunctiva. There was significant difference in the expressions of Cox-2 and VEGF between the pterygium and normal conjunctiva (P < 0.05, P < 0.001).
CONCLUSIONS: There are high Cox-2 and VEGF expressions in pterygium, which suggests that there is abnormal blood vessel multiply in pterygium, and the Cox-2 and VEGF plays an important role in the incidence and development of pterygium. Specific Cox-2 and VEGF inhibitor become a new target for the therapy of pterygium. Specific Cox-2 and VEGF inhibitor become a new target for the therapy of pterygium.